Update: Stellantis: Mean To Lead in Sustainable, Zero-Emission Mobility – IAA
Stellantis aims to lead in sustainable, zero-emission mobility and maintain its strong market position.
Update: Apollo Funds Acquire 20% Of BP’s Trans Adriatic Pipeline For $1 billion
Apollo Funds to invest in bp Pipelines TAP Limited, gaining a stake in Trans Adriatic Pipeline AG for around $1 billion. This move…
Covid-19 May Cause Prolonged Excess Mortality – Swiss Re Report
A report by Swiss Re indicates that COVID-19 could cause prolonged excess mortality, potentially up to 3% in the US and 2.5% in…
Novaris’ Kisqali Cuts Breast Cancer Recurrence Shows Lasting Benefits – ESMO
Novartis' Kisqali in a new analysis showed a 28.5% reduction in the risk of breast cancer recurrence in patients with early breast cancer.…
Fuso Unveils All-Electric eCanter At IAA Transportation With Multiple Body Variants
FUSO is displaying the all-electric eCanter with various body types and safety features at the IAA Transportation event.
Update: Daimler Truck’s Builds New Carbon-Neutral Long-Haul Mercedes-Benz eActros 600
Daimler Truck's focus on CO2-neutral long-distance haulage, with series production of Mercedes-Benz eActros 600 starting in November.
Update: Muscle-Invasive Bladder Cancer: AstraZeneca’s Imfinzi Reduced Recurrence And Death
Imfinzi, in combination with chemotherapy, reduces recurrence risk by 32% and death risk by 25% compared to chemotherapy alone for muscle-invasive bladder cancer…
Merck: Keytruda Combo Improves Survival In Her2-Positive Gastric Cancer -ESMO
Merck & Co. announced that KEYTRUDA® with Trastuzumab and Chemotherapy improves survival in HER2-positive gastric cancer patients compared to Trastuzumab and Chemotherapy alone.…
JPMorgan Chase: $206.73 Dividend Per Preferred Share
JPMorgan Chase declares dividends on Series CC preferred stock
Update: Enhertu Showed 61.6% 1-Yr Progression-Free Survival Destiny-Breast12 Study -ESMO
AstraZeneca's Enhertu displayed significant effectiveness in patients with HER2-positive metastatic breast cancer and brain metastases, achieving a 61.6% progression-free survival rate at one…